Skip to main content

Table 3 Multivariable adjusted associations with composite and wound complicationsa

From: The prevalence of hyperglycemia and its association with perioperative outcomes in gynecologic surgery: a retrospective cohort study

 

Composite complication

(events = 242)

Wound complication

(events = 49)

Patient characteristics

OR (95% CI)

P

OR (95% CI)

P

Hyperglycemiab

1.26 (0.65–2.43)

0.49

1.06 (0.7–0.51)

0.76

Age, yearsc

1.35 (0.94–1.95)

0.11

0.97 (0.7–1.35)

0.88

BMI, kg/m2

1.05 (0.84–1.32)

0.65

1.09 (0.86–1.39)

0.48

Operative timec

1.48 (1.19–1.85)

 < 0.001

1.11 (0.88–1.39)

0.38

Upper quartile EBL

1.29 (1.13–1.47)

 < 0.001

1.00 (0.97–1.03)

0.89

ASA ≥ III

1.11 (0.76-–.61)

0.60

1.09 (0.79–1.51)

0.63

Malignancy

1.18 (0.65–2.16)

0.58

1.09 (0.78–1.53)

0.62

Cardiovascular disease

1.00 (0.68–1.47)

1.00

1.09 (0.79–1.51)

0.610

Diabetes

1.14 (0.68–1.91)

0.61

1.09 (0.78–1.54)

0.61

Surgical approach

(laparotomy vs. MIS)

2.13 (1.39–3.27)

 < 0.001

1.28 (0.92–1.79)

0.14

Division

   

14

  General Gyn/MIGS

Reference

 

Reference

14

  Urogynecology

1.12 (0.7–1.78)

0.64

0.97 (0.69–1.36)

0.85

  Gynecology

0.86 (0.45–1.62)

0.63

1.09 (0.77–1.53)

0.63

  1. ASA American Society of Anesthesiologists, BMI Body mass index, EBL Estimated blood loss, MIGS Division of Minimally Invasive Gynecologic Surgery, MIS Minimally invasive surgical route (i.e., laparoscopic, robotic, or vaginal surgery)
  2. aResults were estimated from multivariable logistic regression models. For wound complication, to account for the limited number of events, penalized maximum likelihood estimation was used. More details are available in the “Materials and methods” section. bHyperglycemia defined as a blood glucose ≥ 140 g/dL. c For continuous variables, OR reflect comparison of third quartile to first quartile